# A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants

> **NCT06581627** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers
- Sickle Cell Disease
- Thalassemia

## Interventions

- **DRUG:** Etavopivat

## Key facts

- **NCT ID:** NCT06581627
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-26
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06581627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06581627, "A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06581627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*